About tapentadol hydrochloride
Tapentadol hydrochloride manufacturers include the originator Grünenthal (Palexia, Nucynta outside the US), Collegium Pharmaceutical (Nucynta in the US) and generic producers, with the first US generics approved in January 2026. Tapentadol is a centrally acting opioid analgesic with a dual mechanism: mu-opioid receptor activation and noradrenaline reuptake inhibition. It is used for moderate to severe acute pain and, as extended-release tablets, for chronic pain including diabetic neuropathic pain. Pharmaceutical companies can source tapentadol tablets and API through out-licensing, supply or technology transfer.
Tapentadol hydrochloride key facts
|
Property |
Tapentadol hydrochloride |
|---|---|
|
INN |
Tapentadol (as hydrochloride) |
|
Molecular formula / weight |
C14H23NO · HCl / 257.8 g/mol |
|
ATC code |
N02AX06 |
|
Drug class |
Opioid analgesic; mu-opioid agonist and noradrenaline reuptake inhibitor |
|
Brand names |
Nucynta, Nucynta ER (US, Collegium); Palexia, Palexia SR (Grünenthal, EU and other markets) |
|
Originator |
Grünenthal (Germany), developed with Johnson & Johnson |
|
Dosage forms and strengths |
Immediate-release tablets 50, 75, 100 mg; extended-release tablets 50–250 mg; oral solution (some markets) |
|
Indications |
Moderate to severe acute pain; severe chronic pain; diabetic peripheral neuropathic pain (extended-release, US) |
|
Control status |
US Schedule II; controlled in the EU and most countries |
|
First approval |
US FDA, November 2008 (immediate release) |
|
Extended-release approval |
US FDA, 2011 |
|
US generic status |
First generics of Nucynta tablets and oral solution approved January 2026 |
Tapentadol hydrochloride manufacturers and licensing history
Grünenthal discovered tapentadol and developed it with Johnson & Johnson. The FDA approved Nucynta immediate-release tablets in November 2008, and Nucynta ER in 2011. In Europe and other markets, Grünenthal sells it as Palexia. US rights moved to Depomed and later to Collegium Pharmaceutical.
The first US generics of Nucynta tablets and oral solution were approved in January 2026. Extended-release products have separate patent and formulation considerations, including abuse-deterrent features.
Tapentadol is a Schedule II opioid in the US and controlled in most countries. Buyers should confirm controlled-substance licences, quotas, GMP status, a DMF and abuse-deterrent formulation data before choosing a dossier partner.
Tapentadol hydrochloride dosage forms and dossier types
Tapentadol is supplied as immediate-release tablets, extended-release tablets and, in some markets, oral solution.
|
Form |
Strengths |
Typical dossier |
Notes |
|---|---|---|---|
|
Tapentadol immediate-release tablets |
50, 75, 100 mg |
US ANDA; EU CTD |
US generics approved January 2026 |
|
Tapentadol extended-release tablets |
50, 100, 150, 200, 250 mg |
US ANDA; EU CTD |
Check patents and abuse-deterrent requirements |
|
Tapentadol oral solution |
Per national MA |
US ANDA; EU CTD |
US generic approved January 2026 |
|
Tapentadol hydrochloride API |
Bulk |
DMF; CEP |
Controlled substance; DEA or national licence |
|
Target market |
Dossier format |
Key requirement |
|---|---|---|
|
United States |
ANDA (eCTD) |
Schedule II; DEA registration and quota |
|
European Union |
EU CTD |
Reference Palexia; narcotics licences |
|
Other markets |
CTD |
Import and export permits for controlled substances |
Tapentadol hydrochloride regulatory and patent status
Tapentadol was approved in the US in November 2008 and is widely approved in Europe and other markets. The first US generics of immediate-release tablets and oral solution were approved in January 2026. Extended-release forms may still be protected by formulation patents. As an opioid, tapentadol carries boxed warnings about addiction, abuse, respiratory depression and serotonin syndrome.
Tapentadol hydrochloride mechanism of action and therapeutic use
Tapentadol activates mu-opioid receptors and blocks noradrenaline reuptake in the spinal cord and brain. The noradrenaline effect adds pain relief, especially for nerve pain, and allows lower opioid activity than some other opioids. Tapentadol is used for moderate to severe acute pain and, in extended-release form, for severe chronic pain, including diabetic nerve pain.
Tapentadol hydrochloride licensing and sourcing
Tapentadol suppliers and licensing partners typically offer dossier out-licensing, finished-product supply or technology transfer. Buyers usually compare GMP status, controlled-substance licences, formulation type and territory availability. Current offers and supplier contacts are listed among the tapentadol hydrochloride manufacturers on Pipelinepharma.
Frequently asked questions about tapentadol hydrochloride
Who are the main tapentadol manufacturers? Grünenthal sells Palexia outside the US, and Collegium sells Nucynta in the US. Generic makers received US approvals in January 2026.
Is there a generic version of tapentadol? Yes. The first US generics of Nucynta tablets and oral solution were approved in January 2026.
What forms and strengths of tapentadol are available? Tapentadol is available as 50–100 mg immediate-release tablets, 50–250 mg extended-release tablets and oral solution in some markets.
Is tapentadol a controlled substance? Yes. Tapentadol is a Schedule II opioid in the US and controlled in most countries.
How is tapentadol different from tramadol? Both combine opioid and monoamine effects. Tapentadol acts directly without needing liver activation and has a stronger opioid effect.
Popular Searches
Want unlimited access to the Pipelinepharma database?
Become a subscriber to unlock:
-
Streamlined product sourcing: access the only CTD dossier pipeline and sourcing platform.
-
Direct connections: communicate directly with CTD dossier owners and manufacturers with no brokerage fees.
-
Higher profitability: compare multiple supplier offers and secure the best commercial terms.
-
Expanded network: view supplier portfolios and stay updated on new products.
-
Value-added product ideas: discover products with lower competition potential.
-
Access to marketing authorizations for sale: find already registered products in your target markets.